Astrazeneca (AZN) Receivables - Net (2009 - 2026)

Astrazeneca has reported Receivables - Net for 18 years, with the latest figure at $14.3 billion in Q2 2026.

• On a quarterly basis, Receivables - Net rose 1.14% year-over-year to $14.3 billion in Q2 2026; TTM through Jun 2026 was $14.3 billion, a 1.14% increase from a year earlier, with the FY2025 full-year figure at $15.2 billion, up 17.0% from the prior year.
• Receivables - Net was $14.3 billion for Q2 2026 at Astrazeneca, up from $14.1 billion in the prior quarter.
• The five-year high for Receivables - Net was $15.2 billion in Q4 2025, with the low at $8.7 billion in Q1 2022.
• Average Receivables - Net over 5 years is $11.9 billion, with a median of $11.6 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Receivables - Net jumped 40.15% in 2022, then declined 0.41% in 2024.
• Over 5 years, Receivables - Net stood at $10.5 billion in 2022, then increased by 15.26% to $12.1 billion in 2023, then increased by 6.98% to $13.0 billion in 2024, then advanced by 17.0% to $15.2 billion in 2025, then slipped by 5.58% to $14.3 billion in 2026.
• The last three Receivables - Net figures came in at $14.3 billion (Q2 2026), $14.1 billion (Q1 2026), and $15.2 billion (Q4 2025), per Business Quant data.